Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

proCOLON

Financiado

First-in-class beta-catenin inhibitor as treatment for colorectal cancer

With more than 1.9 million new cases and 935,000 related deaths in 2020, colorectal cancer (CRC) is the third most common cancer in men and the second in women. While surgery is the main treatment option for lower grade CRC, patie... ver más

31/10/2023

STICHTING VU

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

STICHTING VU No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-10-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2022-POC1: ERC PROOF OF CONCEPT GRANTS1

I+D

Cerrada hace 3 años

0% 100% 100%

1 Participantes

STICHTING VU

150.00K€ | Lider

Proyectos interesantes

PDC2021-121464-I00 GENERACION Y CARACTERIZACION DE ANTICUERPOS WNT-11 RECOMBINA... 138K€ Cerrado

PID2020-117649RB-I00 DESARROLLO DE TERAPIAS PERSONALIZADAS PARA CANCERES DEPENDIE... 248K€ Cerrado

SAF2013-44267-R CDK8 NUEVA DIANA EN TERAPIA DEL CANCER. RELEVANCIA DE LA ACT... 121K€ Cerrado

SAF2008-01512 SEÑALIZACION POR WNT, RECEPTORES EPH Y CANCER DE COLON: UN A... 351K€ Cerrado

PRE2021-101010 DESARROLLO DE TERAPIAS PERSONALIZADAS PARA CANCERES DEPENDIE... 101K€ Cerrado

UNMET 'UNMET' - Uncovering Mechanisms and Establishing Strategies... 215K€ Cerrado

Últimas noticias

30-11-2024: Cataluña Gestión For... Se ha cerrado la línea de ayuda pública: Gestión Forestal Sostenible para Inversiones Forestales Productivas para el organismo:

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

Duración del proyecto: 18 meses Fecha Inicio: 2022-04-07
Fecha Fin: 2023-10-31

Líder del proyecto

STICHTING VU

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto With more than 1.9 million new cases and 935,000 related deaths in 2020, colorectal cancer (CRC) is the third most common cancer in men and the second in women. While surgery is the main treatment option for lower grade CRC, patients with unresectable lesions are treated with chemotherapy. Related therapies are associated with severe drawbacks, such as systemic toxicity, low response rate, and unpredictable resistance. Molecular targeted therapies have emerged as a promising strategy to specifically target cancer cells. For CRC, the inhibition of the Wnt signalling pathway has moved into the focus of novel therapeutic approaches as it is hyperactivated in 80% of all cases. Within the pathway, the protein beta-catenin is considered a particularly attractive target. However, classic small molecule targeting strategies have failed to provide any approved drugs that inhibit beta-catenin so far. We have identified a family of peptidomimetic agents that bind beta-catenin and inhibit its interaction with the TCF/LEF transcription factors. For the first time, it was possible to obtain a crystal structure of a synthetic molecule bound to a therapeutically very attractive site on beta-catenin. In addition, we have confirmed cellular activity of these inhibitors verifying selective inhibition of the Wnt signalling pathway. These findings provide the ideal starting point for the development of novel therapeutics for Wnt-dependent cancers, in particular for CRC. These first-in-class inhibitors will provide the basis for the development of therapeutics that selectively inhibit oncogenic Wnt signalling thereby affecting the viability of corresponding cancer cells. This can enable targeted therapies for Wnt-dependent forms of CRC.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores